Conclusions
We have demonstrated that bimatoprost implant biodegradation in the ARTEMIS phase 3 studies showed some degree of variability among patients. Clinically significant implant biodegradation was observed in most patients by 12 months. Clinical studies are in progress to further understand implant biodegradation and the ideal timing for implant re-administration.